ArticleClinical and experimental medicine2026
CD59 silencing enhances doxorubicin sensitivity in DLBCL cells and is associated with poor prognosis in patients treated with CHOP regimen.
Linzhu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.